Investigational drugs in development for hypertriglyceridemia: a coming-of-age story. (2nd December 2019)

• Record Type: Journal Article
• Authors: Rhainds, David; Brodeur, Mathieu R.; Tardif, Jean-Claude
• Is Part Of: Expert opinion on investigational drugs. Volume 28:Number 12(2019)
• Page Start: 1059
• Page End: 1079
• Publication Date: 2019-12-02
• Subjects: Hypertriglyceridemia -- PPAR alpha agonist -- omega-3 fatty acids -- apolipoprotein C-III -- angiopoietin-like 3 -- microsomal transfer protein; Drugs -- Design -- Periodicals; Drugs, Investigational -- Bibliography; Drugs, Investigational -- Periodicals; 615.1
• DOI: 10.1080/13543784.2019.1696772
• Languages: English
• ISSNs: 1354-3784

Abstract

ABSTRACT: Introduction : Elevated triglyceride (TG) level is a prevalent condition in the general population and in patients with cardiovascular (CV) risk even under statin therapy. Severe hypertriglyceridemia (HTG) puts patients at risk for acute pancreatitis. Several TG-lowering drugs failed in clinical trials, but subgroup analyses suggest that high-risk patients, such as those with atherogenic dyslipidemia or diabetes, benefit from TG lowering. Areas covered : We review advances for TG-lowering drugs in clinical development. These include selective PPARα modulators, omega-3 fatty acid formulations that have been approved for severe HTG, and inhibitors of apolipoprotein C-III, angiopoietin-like-3 or microsomal transfer protein. Lessons learned from the success of the phase 3 trial REDUCE-IT with high-dose icosapent ethyl are also reviewed. Expert opinion : We believe that TG-lowering therapies are coming of age as they will allow to treat patients with high CV risk and moderate HTG, including T2D subjects, as well as patients with severe HTG or even homozygous familial hypercholesterolemia, all of which being 'optimally' treated with a statin. More studies on the impact of therapy on quality of life in patients with severe HTG should be conducted with the help of patient registries.